Association between the COX-2 rs689466 polymorphism and antipsychotic treatment: Impact on HDL cholesterol changes in clozapine-treated psychosis patients
Prostaglandins, Leukotrienes and Essential Fatty Acids · 2025
DOI: 10.1016/j.plefa.2025.102665 ↗Kurz gefasst
Fachartikel in der Zeitschrift Prostaglandins, Leukotrienes and Essential Fatty Acids, 2025. Verfasst von Sergej Nadalin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, General Hospital "Dr. Josip Benčević", Slavonski Brod, Croatia; School of Medicine, Catholic University of Croatia, Zagreb,…. Hauptthemen laut MEDLINE: Clozapine, Antipsychotic Agents, Cyclooxygenase 2, Cholesterol, HDL. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: University of Rijeka.
Abstract (Originalsprache)
Several studies have shown antipsychotic effects of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib as an add-on treatment to antipsychotic treatment. The functional rs689466 (A/G) polymorphism in the gene encoding COX-2 (also known as the prostaglandin-endoperoxide synthase 2 gene) has been correlated with schizophrenia risk and the niacin skin flush response among chronic patients under antipsychotic treatment. Here, we investigated whether this polymorphism was associated with antipsychotic treatment in a group of total psychosis patients (N = 186), as well as a subgroup of patients treated with clozapine (N = 74). Antipsychotic-naïve first-episode patients and non-adherent chronic psychosis patients were genotyped by polymerase chain reaction/restriction fragment length polymorphism analysis. At baseline and after 8 weeks of treatment with various antipsychotic medications, we assessed the patients' Positive and Negative Syndrome Scale (PANSS) scores, factors, and metabolic syndrome-related parameters, including fasting plasma lipid and glucose levels and body mass index. In the total patient group, the COX-2 polymorphism was not associated with PANSS psychopathology scores or metabolic parameters. However, in the subgroup of patients treated with clozapine, the COX-2 polymorphism was associated with changes in plasma HDL cholesterol. Specifically, compared to patients homozygous for the A allele, the subgroup of patients treated with clozapine and positive for the G allele (i.e., GG or AG genotype) exhibited significantly higher increases in HDL cholesterol levels. The COX-2 polymorphism had a moderate effect size but made a relatively weak contribution to variations in the HDL cholesterol level (∼9.6 %).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, General Hospital "Dr. Josip Benčević", Slavonski Brod, Croatia; School of Medicine, Catholic University of Croatia, Zagreb, Croatia. Electronic address: sergej.nadalin@medri.uniri.hr.
- Department of Psychiatry, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia.
- University Psychiatric Hospital "Vrapče", Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia.
- School of Medicine, Catholic University of Croatia, Zagreb, Croatia; Department of Psychiatry, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia.
- Hospital pharmacy, Clinical Hospital Center Rijeka, Rijeka, Croatia.
- Department of Medical Biology and Genetics, Faculty of Medicine, University of Rijeka, Rijeka, Croatia.
Förderung
- University of Rijeka
Zitieren
APA
Nadalin, S., Ljoka, I., Savić, A., Silić, A., Peitl, V., Karlović, D., Vilibić, M., Zatković, L., & Buretić-Tomljanović, A. (2025). Association between the COX-2 rs689466 polymorphism and antipsychotic treatment: Impact on HDL cholesterol changes in clozapine-treated psychosis patients. Prostaglandins, Leukotrienes and Essential Fatty Acids. https://doi.org/10.1016/j.plefa.2025.102665
Vancouver
Nadalin S, Ljoka I, Savić A, Silić A, Peitl V, Karlović D, et al. Association between the COX-2 rs689466 polymorphism and antipsychotic treatment: Impact on HDL cholesterol changes in clozapine-treated psychosis patients. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2025. doi:10.1016/j.plefa.2025.102665
BibTeX
@article{Nadalin2025,
author = {Nadalin, Sergej and Ljoka, Ivan and Savić, Aleksandar and Silić, Ante and Peitl, Vjekoslav and Karlović, Dalibor and Vilibić, Maja and Zatković, Lena and Buretić-Tomljanović, Alena},
title = {Association between the COX-2 rs689466 polymorphism and antipsychotic treatment: Impact on HDL cholesterol changes in clozapine-treated psychosis patients},
journal = {Prostaglandins, Leukotrienes and Essential Fatty Acids},
year = {2025},
doi = {10.1016/j.plefa.2025.102665}
}
EUVIMED